Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

NCT02982941 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroblastoma
Rhabdomyosarcoma
Osteosarcoma
Ewing Sarcoma
Wilms Tumor
Desmoplastic Small Round Cell Tumor

Interventions

DRUG: Enoblituzumab

Sponsor

MacroGenics